Estados Unidos · Bolsa y Finanzas · The Motley Fool

Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet

Publicado por The Motley Fool · Estados Unidos hace 9 h

Zepbound was a breakthrough. It became the first medicine to mimic the GLP-1 and GIP gut hormones and be approved for weight loss. Its main competitor, Wegovy, only mimics GLP-1.…

Leer el artículo completo en The Motley Fool Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.fool.com)

Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet

También te puede interesar

'Uptober' Starts Green as Bitcoin ETFs Draw $134 Million

Private Equity Firms Double Down on Fossil Fuels

American Airlines adds cash-and-miles bookings as loyalty battle heats up

Gen Z is poised to be wealthier than millennials but despair over economy — ‘they get spammed and scammed, and there are tons of fake jobs out there’

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

This NYC startup requires 4 days in office but just let everyone work remote for a whole month

Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet

Compartir

También te puede interesar

'Uptober' Starts Green as Bitcoin ETFs Draw $134 Million

Private Equity Firms Double Down on Fossil Fuels

American Airlines adds cash-and-miles bookings as loyalty battle heats up

Gen Z is poised to be wealthier than millennials but despair over economy — ‘they get spammed and scammed, and there are tons of fake jobs out there’

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

This NYC startup requires 4 days in office but just let everyone work remote for a whole month